Literature DB >> 12742197

The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries.

Martin A Schreiber1, John B Holcomb, Ulla Hedner, Susan I Brundage, Joseph M Macaitis, Nori Aoki, Zhi Hong Meng, David J Tweardy, Keith Hoots.   

Abstract

BACKGROUND: Recombinant Factor VIIa (rFVIIa) has been used to decrease bleeding in a number of settings, including hemophilia, liver transplantation, intractable bleeding, and cirrhosis. It has also been shown to reduce bleeding in coagulopathic pigs with Grade V liver injuries when used as an adjunct to packing. This study was performed to determine if rFVIIa would reduce blood loss after a Grade V liver injury in noncoagulopathic pigs when used as sole therapy. STUDY
DESIGN: Thirty normothermic animals were randomized to receive either 150 microg/kg of rFVIIa or normal saline intravenously. After laparotomy and splenectomy, a standardized Grade V liver injury was made with a liver clamp. Thirty seconds after injury, blinded therapy was given. Blood loss was measured 15 minutes after injury and the abdomen was closed. Animals were resuscitated to their baseline blood pressure and the study was continued for 2 hours. Serial coagulation parameters were obtained. Following the study period, blood loss was measured and an autopsy was performed. Grossly normal areas of lung were examined for evidence of intravascular thrombosis.
RESULTS: Mean Factor VII:C levels increased 155-fold in the treatment group after infusion of rFVIIa. The mean prothrombin time in the treatment group decreased from 9.8 +/- 0.4 seconds to 7.3 +/- 0.2 seconds and remained significantly different from the control group throughout the study (p < 0.01). There were no differences in other coagulation parameters. Mean initial blood loss was 822 +/- 266 mL in the treatment group and 768 +/- 215 mL in the control group (p = 0.6). Rebleeding blood volume was 397 +/- 191 mL in the treatment group and 437 +/- 274 mL (p = 0.6) in the control group. Lung histology revealed no evidence of abnormal microvascular thrombosis.
CONCLUSIONS: rFVIIa does not reduce blood loss after Grade V liver injury when it is used as sole therapy in warm noncoagulopathic pigs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742197     DOI: 10.1016/S1072-7515(02)01835-5

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  6 in total

1.  Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.

Authors:  Jun Zhang; Robert F Groff; Xiao-Han Chen; Kevin D Browne; Jason Huang; Eric D Schwartz; David F Meaney; Victoria E Johnson; Sherman C Stein; Rasmus Rojkjaer; Douglas H Smith
Journal:  Exp Neurol       Date:  2008-01-05       Impact factor: 5.330

2.  Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application.

Authors:  Nicolas Jabbour; Singh Gagandeep; Rodrigo Mateo; Linda Sher; Earl Strum; John Donovan; Jeffrey Kahn; Christian G Peyre; Randy Henderson; Tse-Ling Fong; Rick Selby; Yuri Genyk
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 3.  Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.

Authors:  Alicia M Mohr; John B Holcomb; Richard P Dutton; Jacques Duranteau
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 4.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 5.  Preclinical trauma studies of recombinant factor VIIa.

Authors:  Martin A Schreiber; John B Holcomb; Rasmus Rojkjaer
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 6.  Methods for improved hemorrhage control.

Authors:  John B Holcomb
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.